TY - JOUR
AU1 - Okubo, Tomomi
AU2 - Atsukawa, Masanori
AU3 - Tsubota, Akihito
AU4 - Toyoda, Hidenori
AU5 - Shimada, Noritomo
AU6 - Abe, Hiroshi
AU7 - Kato, Keizo
AU8 - Hayama, Korenobu
AU9 - Arai, Taeang
AU1 - Nakagawa-Iwashita, Ai
AU1 - Itokawa, Norio
AU1 - Kondo, Chisa
AU1 - Kawamoto, Chiaki
AU1 - Iio, Etsuko
AU1 - Tanaka, Yasuhito
AU1 - Kumada, Takashi
AU1 - Iwakiri, Katsuhiko
AB - Background/aim To evaluate the efficacy and safety of ledipasvir and sofosbuvir therapy for genotype 1b in chronic hepatitis C patients with chronic kidney disease (CKD) stage 3. Methods In a multicenter collaborative retrospective study, 706 patients who have received ledipasvir which is NS5A inhibitor, and sofosbuvir 400 mg which is NS5B nucleoside polymerase inhibitor daily for 12 weeks between September 2015 and January 2017 were subjected to this analysis. Virologic response and adverse events in patients with CKD stage 3 were compared with those in patients with CKD stages 1 and 2. Results The rates of sustained virologic response (SVR) were 97.0% in patients with CKD stage 1, 97.1% in patients with CKD stage 2, and 94.7% in patients with CKD stage 3, respectively. There were no significant differences in the SVR rates between CKD stages 1 and 2, and CKD stage 1 and stage 3. The incidence of adverse events over than grade 2 was 0% in patients with CKD stage 1, 0.5% in patients with CKD stage 2, and 3.0% in patients with CKD stage 3, respectively. For treatment and follow-up period, eGFR levels in the patients with CKD stage 3 were not worsened compared to those 
TI - Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment
JF - Hepatology International
DO - 10.1007/s12072-018-9859-9
DA - 2018-03-29
UR - https://www.deepdyve.com/lp/springer-journals/efficacy-and-safety-of-ledipasvir-sofosbuvir-for-genotype-1b-chronic-fKu0s0p09Y
SP - 133
EP - 142
VL - 12
IS - 2
DP - DeepDyve
ER -